Changes of serum TIMP-1, MMP-2 and GP73 levels in patients with hepatitis B cirrhosis treated with entecavir

Abstract

Abstract: Objective To investigate the changes of serum tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metalloproteinase-2 (MMP-2) and golgi protein 73 (GP73) levels in patients with hepatitis B cirrhosis treated with entecavir. Methods Seventy-six patients with hepatitis B cirrhosis admitted to our hospital from June 2019 to May 2020 were enrolled, and they were randomly divided into control group and study group, with 38 cases in each group. The control group was treated with routine treatment, and the observe group was added with entecavir treatment. The levels of total bilirubin (TBil), albumin (Alb), international normalized ratio (INR), serum TIMP-1, serum MMP-2, serum GP73 and imaging indexes were compared between the 2 groups. The clinical efficacy and adverse reactions of the 2 groups were compared. Results After 3, 6, 12 months of treatment, TBil of study group were (30.1±5.3) μmol/L, (27.6±4.8) μmol/L, (22.4±4.2) μmol/L, respectively. The Alb level of study group at 3, 6, 12 months after treatment were (28.5±3.7) g/L, (32.6±4.5) g/L, (39.4±5.2) g/L, which were significantly higher than those of control group [(23.7±3.5) g/L, (29.1±4.2) g/L, (34.2±4.3) g/L] (TBil: t=3.518, 2.288, 46.80; INR: t=4.359, 4.258, 4.052; all P<0.05). The INR of study group at 3, 6, 12 months after treatment were (1.4±0.1), (1.2±0.1), (1.1±0.0), which were significantly lower than those of control group [(1.5±0.1), (1.3±0.1), (1.2±0.1)] (t=5.810, 3.505, 4.751, all P<0.05). After 3, 6, 12 months of treatment, the serum TIMP-1 of study group were (295.4±45.7) ng/mL, (262.3±40.2) ng/mL, (234.2±32.8) ng/mL, the serum MMP-2 level of study group were (726.5±66.3) ng/mL, (683.2±59.7) ng/mL, (601.4±52.6) ng/mL, the serum GP73 level of study group were (73.1±9.5) ng/mL, (54.1±7.8) ng/mL, (35.4±6.3) ng/mL, which were significantly lower than those in control group [TIMP-1: (317.2±50.1) ng/mL, (281.4±42.7) ng/mL, (251.8±39.2) ng/mL, MMP-2: (759.8±69.3) ng/mL, (711.4±57.2) ng/mL, (631.8±55.2) ng/mL, GP73: (82.8±10.7) ng/mL, (62.4±8.1) ng/mL, (50.7±7.6) ng/mL](TIMP-1: t=2.164, 2.008, 2.123, MMP-2: t=2.140, 2.103, 2.458, GP73: t=4.179, 4.550, 9.554, all P<0.05). After 3, 6, 12 months of treatment, the liver hardness of study group (17.6±4.1) kPa, (14.1±3.6) kPa, (13.1±3.2) kPa was significantly lower than that of the control group [(19.8±4.3) kPa, (15.8±3.9) kPa, (14.6±3.7) kPa] (t=2.283, 2.091, 2.142, all P<0.05). After 6, 12 months later treatment, the spleen thickness of the study group [(41.6±3.2) mm, (40.5±2.6) mm] was lower than that of control group [(43.7±3.1) mm, (41.9±2.7) mm] (t=2.906, 2.302, all P<0.05). Conclusion Entecavir can improve the liver function, reduce the liver hardness value, spleen thickness and regulate the serum TIMP-1, MMP-2, GP73 levels in patients with hepatitis B cirrhosis.

Key words: Entecavir, Hepatitis B, Cirrhosis, Tissue inhibitor of metalloproteinase-1, Matrix metalloproteinase-2, Golgi protein 73

LIU Wen-yan, MA Shi-he, HUANG Gui, CHEN Chong, ZHENG Yi-bin. Changes of serum TIMP-1, MMP-2 and GP73 levels in patients with hepatitis B cirrhosis treated with entecavir[J]. Chinese Hepatolgy, 2022, 27(5): 536-539.

References

[1] Zhong HJ, Sun HH, Xue LF, et al. Differential hepatic features presenting in wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis. World J Gastroenterol, 2019, 25(3):378-387.
[2] 王禅, 秦伟, 戴勇, 等. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者临床疗效及其对外周血T淋巴细胞亚群的影响. 实用肝脏病杂志, 2019, 22(1):102-105.
[3] Schuppan D, Ashfaq-Khan M, Yang AT, et al. Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol, 2018, 27(11):435-451.
[4] Zhang T, Yang Y, Wang B, et al. Meta-analysis of influences of biejiajian Pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: protocol of systematic review and meta-analysis. Medicine, 2019, 98(51):18458.
[5] Beime J, Krech T, Hischke S, et al. Tissue inhibitor of metalloproteinase 1 and ast-to-platelet ratio index as noninvasive biomarkers predict allograft fibrosis after pediatric liver transplantation. Clin Transplant, 2019, 33(10):13676.
[6] Si N, Kanazawa H, Okuyama K, et al. Involvement of catechols in acteoside in the activation of promatrix metalloproteinase-2 and membrane type-1-matrix metalloproteinase expression via a phosphatidylinositol-3-kinase pathway in human dermal fibroblasts. Biol Pharm Bull, 2018, 41(10):1530-1536.
[7] Gatselis NK, Tornai T, Shums Z, et al. Golgi protein-73: a biomarker for assessing cirrhosis and prognosis of liver disease patients. World J Gastroenterol, 2020, 26(34):5130-5145.
[8] 徐小元, 丁惠国, 李文刚, 等. 肝硬化诊治指南. 临床肝胆病杂志, 2019, 10(11):47-51.
[9] 张翀, 丁洋, 窦晓光. 从指南到指导意见:2018美国肝病学会慢性乙型肝炎预防诊断及治疗指导意见解读. 中国实用内科杂志, 2018, 38(6):545-548.
[10] Dertli R, Keskin M, Byk M, et al. Dynamic thiol-disulfide homeostasis is disturbed in hepatitis B virus-related chronic hepatitis and liver cirrhosis. Turk J Med Sci, 2018, 48(5):985-992.
[12] Wu X, Shi Y, Zhou J, et al. Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. Expert Opin Biol Ther, 2018, 18(1):61-69.
[13] 李劲松, 曾庆贵, 钟俊. 恩替卡韦对乙型肝炎肝硬化患者肝脏硬度的影响. 西南国防医药, 2018, 12(1):67-68.
[14] Belenkov YN, Privalova EV, Iusupova AO, et al. Markers of vascular wall fibrosis metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with ischemic heart disease with and without concomitant type-2 diabetes mellitus. Kardiologiia, 2019, 59(5):61-66.
[15] 李洋阳, 王国兴, 张天鹏, 等. 重症急性胰腺炎合并肝功能异常患者预后的相关因素分析. 临床和实验医学杂志, 2020, 19(8):837-841.
[16] 姚小健, 黄红霞, 陈勇. 乙型肝炎肝硬化患者血清血小板衍生生长因子和叶酸水平变化. 实用肝脏病杂志, 2018, 21(1):76-79.
[17] Xavier SA, Vilas-Boas R, Boal Carvalho P, et al. Assessment of prognostic performance of albumin-bilirubin, child-pugh, and model for end-stage liver disease scores in patients with liver cirrhosis complicated with acute upper gastrointestinal bleeding. Eur J Gastroenterol Hepatol, 2018, 30(6):652-658.
[18] Chen LC, Shibu MA, Liu CJ, et al. ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts. Chem Biol Interact, 2019, 306(12):62-69.
[19] 袁媛, 陈洁, 杨雪梅, 等. 复方甘草酸苷治疗乙型肝炎肝硬化的疗效及对血清IL-17,IL-6,TGF-β和MMP-2水平的影响. 临床与病理杂志, 2020, 40(8):171-177.
[20] 程华, 鞠辉, 宋德顺, 等. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析. 实用肝脏病杂志, 2019, 22(4):45-48.

[1]	FANG Qing-qing, CHEN Ying, CHEN Wei, JIAN You-rong, LI Yu, ZHU Zi-hua, SHEN Dan Jie, CHEN Shi-yao, LI Feng. Risk factors of rebleeding after endoscopic treatment for esophagogastric varices in liver cirrhosis patients [J]. Chinese Hepatolgy, 2022, 27(5): 526-530.
[2]	LI Qi, ZENG A-juan, DING Hui-guo, LI Lei. Analysis on the influencing factors of gallbladder wall thickening in Wilson's disease-associated cirrhosis [J]. Chinese Hepatolgy, 2022, 27(5): 531-535.
[3]	FENG Dan-ni, ZHANG Da-li, HE Xi, ZHANG Li-juan, ZHOU Shuang-nan, GAO Yin-jie, LIU Hong-ling. Case-control study of thrombocytopenia in liver transplant recipients with alcoholic cirrhosis [J]. Chinese Hepatolgy, 2022, 27(5): 540-542.
[4]	WANG Xiao-wei, SUN Jing, WANG Dong. Effect of nonalcoholic fatty liver disease on antiviral treatment response of children and adolescents with chronic hepatitis B [J]. Chinese Hepatolgy, 2022, 27(5): 557-560.
[5]	CHEN Jing-yu, QI Wei, HU Ming-le, LI Hua-dong, WANG Jing. Correlation between HBV pgRNA level and the risk of recurrence in patients with chronic hepatitis B after withdrawal of antiviral drug [J]. Chinese Hepatolgy, 2022, 27(4): 413-417.
[6]	SUN Ji-yun, MA Xiao-yan, LIU Huan, WANG Ya-jie. Comparison of the performance between the 2 magnetic particle chemiluminescence kits for detection of hepatitis B virus surface antigen [J]. Chinese Hepatolgy, 2022, 27(4): 418-420.
[7]	WANG Ai-min, MEI Xue, GUO Hong-ying , YUAN Wei, ZHANG Yu-yi, QIAN Zhi-ping, WANG Jie-fei, LIU Yu. Clinical value of 4 scoring systems in evaluating the short-term prognosis of patients suffering from HBV-ACLF complicated with esophageal gastric variceal bleeding [J]. Chinese Hepatolgy, 2022, 27(4): 421-425.
[8]	GUO Feng, DOU Jing, WANG Xiao-bo, MA Yan, LE Yong-hong, WANG Xiao-zhong. Pathological and clinical features of liver biopsy in ALT < 2 ULNpatients with hepatitis B-related liver fibrosis [J]. Chinese Hepatolgy, 2022, 27(4): 431-436.
[9]	WEI Wang-jiang, Han Xiao-tao, Bai Lu. A study on heart disease in patients with hepatitis B virus-related cirrhosis [J]. Chinese Hepatolgy, 2022, 27(4): 437-439.
[10]	WANG Tian-bao, WEI Hai-gang, XU Xin-sheng. Evaluation of liver fibrosis stage in chronic hepatitis B patients by spleen stiffness and volume measurement with magnetic resonance elastography [J]. Chinese Hepatolgy, 2022, 27(4): 443-446.
[11]	CHEN Li-fen, YAO Chao-guang, LAN Jing, HUANG Li, QIN Dong-lin, OU Qin, WU Xiao-yun, HUANG Shuang-xiang. A comparison between MR elastography and endoscopic ultrasonography for the diagnosis of esophageal and gastric varices in liver cirrhotic patients [J]. Chinese Hepatolgy, 2022, 27(4): 447-450.
[12]	LI Jian, CHENG Jing-hua, TIAN Jie, LI You-xuan, LIAO De-zhong, XU Jing. A comparative analysis between the clinical features of hepatitis B virus-related and nonvirus-related primary liver cancers [J]. Chinese Hepatolgy, 2022, 27(4): 460-465.
[13]	LU Yan-ling, LI Xiao-hong, CHEN Hai-tao. A study on the relationship between serum HBV pgRNA, HBV DNA and HBeAg levels in patients with chronic hepatitis B [J]. Chinese Hepatolgy, 2022, 27(3): 302-304.
[14]	LI Xiang, WANG Yan-bai, WANG Yin-feng, HUANG Xue-lan. The relationship between ANRIL and miR-122 expression in patients with occult hepatitis B viral infection [J]. Chinese Hepatolgy, 2022, 27(3): 305-310.
[15]	HUANG Fu-tong, LIN Yong-mei, LU Chang-chun, HE Ying, RAO Ke-meng. Correlation between the ratio of PA/TB, serum level of AFP and the efficacy and prognosis of sequential plasma exchange with DPMAS in HBV-ACLF patients [J]. Chinese Hepatolgy, 2022, 27(3): 325-329.